Mitochondrial Myopathies: Clinical Trials

12 trials for Mitochondrial Myopathies, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 4 recruiting, 1 not yet recruiting. 12 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 112Completed 7, Recruiting 4, Not yet recruiting 1
Phase 23Completed 2, Not yet recruiting 1

Follow Mitochondrial Myopathies: new trials by email Literature Review of Mitochondrial Myopathies trials Research Report on Mitochondrial Myopathies

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)
Glycerol Tributyrate - MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
Phase 1 / Phase 2Not yet recruitingGeorge Washington University242027-03-012026-10-05
Validation of Nanosensor Oxygen Measurement
Nanosensor - MItochondrial Myopathies, Mitochondrial Disease
Phase 1RecruitingChildren's Hospital of Philadelphia702025-01-022026-10-07
Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD).
Promoting Resilience in Stress Management (PRISM), Clinical-focused narrative (CFN) - Mitochondrial Diseases, Mitochondrial Myopathies
Phase 1 / Phase 2CompletedChildren's Hospital of Philadelphia162023-09-222024-11-29
Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels
N-Acetylcysteine - Mitochondrial Disease
Phase 1RecruitingMichio Hirano, MD182023-07-062026-01-23
Applying pGz in Mitochondrial Disease
Cardiopulmonary Exercise Testing, pGz Bed, Gentle Jogger - Mitochondrial Myopathies, Mitochondrial Diseases
Phase 1RecruitingChildren's Hospital of Philadelphia902023-03-222025-11-10
Validation of Oxygen Nanosensor in Mitochondrial Myopathy
Nanosensor - Mitochondrial Myopathies, Mitochondrial Diseases
Phase 1RecruitingChildren's Hospital of Philadelphia242023-01-172026-02-18
L-Citrulline Dose Finding Safety Study in MELAS
L-Citrulline - MELAS Syndrome
Phase 1CompletedBaylor College of Medicine102021-04-222024-06-26
MABs Therapy m.3243A>G Mutation Carriers
autologous mesoangioblasts - Mitochondrial Myopathies
Phase 1CompletedMaastricht University62020-03-012024-01-17
A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease
KL1333, Placebo Oral Tablet - Mitochondrial Diseases, Mitochondrial Respiratory Chain Deficiencies
Phase 1CompletedAbliva AB722019-03-182021-10-20
Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers
KL1333 25 mg, KL1333 50 mg, KL1333 100 mg - MELAS Syndrome, Mitochondrial Respiratory Chain Deficiencies
Phase 1CompletedYungjin Pharm. Co., Ltd.602017-06-262018-04-27
A Dose-escalating Clinical Trial With KH176
KH176, placebo - MELAS, LHON
Phase 1CompletedKhondrion BV322015-05-012021-10-18
Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy
elamipretide (low dose), elamipretide (intermediate dose), elamipretide (high dose) - Mitochondrial Myopathy
Phase 1 / Phase 2CompletedStealth BioTherapeutics Inc.362015-02-012019-12-27

Narrower conditions

Mitochondrial Diseases (9)  ·  MELAS Syndrome (7)  ·  Acidosis, Lactic (1)  ·  Anxiety Disorders (1)  ·  Cognition Disorders (1)  ·  Deafness (1)  ·  Diabetes Mellitus (1)  ·  Dystonia (1)  ·  Hearing Loss (1)  ·  Kearns-Sayre Syndrome (1)  ·  Leigh Disease (1)  ·  MERRF Syndrome (1)  ·  Migraine Disorders (1)  ·  Mitochondrial Encephalomyopathies (1)

Broader conditions

Metabolic Diseases (12)  ·  Musculoskeletal Diseases (12)  ·  Nervous System Diseases (12)  ·  Neuromuscular Diseases (12)  ·  Nutritional and Metabolic Diseases (12)  ·  Muscular Diseases (11)  ·  Brain Diseases (7)  ·  Brain Diseases, Metabolic (7)  ·  Brain Diseases, Metabolic, Inborn (7)  ·  Cardiovascular Diseases (7)  ·  Central Nervous System Diseases (7)  ·  Cerebral Small Vessel Diseases (7)  ·  Cerebrovascular Disorders (7)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7)  ·  Genetic Diseases, Inborn (7)

Interventions

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (1)  ·  Acetylcysteine (1)  ·  Citrulline (1)  ·  Exercise Test (1)  ·  arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide (1)

Sponsors

Children's Hospital of Philadelphia (4)  ·  Abliva AB (1)  ·  Baylor College of Medicine (1)  ·  George Washington University (1)  ·  Khondrion BV (1)  ·  Maastricht University (1)  ·  Michio Hirano, MD (1)  ·  Stealth BioTherapeutics Inc. (1)  ·  Yungjin Pharm. Co., Ltd. (1)

Countries

United States (8)  ·  Belgium (1)  ·  Netherlands (1)  ·  South Korea (1)  ·  United Kingdom (1)

Top investigators

Anne Chiaramello, Ph.D. (1)  ·  Debra Regier, M.D., Ph.D. (1)  ·  Elizabeth M McCormick, MS (1)  ·  Karin Faber, Prof. PhD MD (1)  ·  Kyung-Sang Yu, MD., MBA (1)  ·  Matilda Hugerth, MSc (1)  ·  Michio Hirano, MD (1)  ·  Wei-Liang Chen, M.D. (1)  ·  Zarazuela Zolkipli-Cunningham (1)  ·  Zarazuela Zolkipli-Cunningham, MBChB, MRCP (1)  ·  Zuela Zolkipli-Cunningham, MBChB, MRCP (1)

Results publications

PMID 29037240

NIH funding

U54NS078059 (3), UH3TR003897 (1)